Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Stocks Undercut as Little Progress is seen in U.S. Debt Ceiling Talks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.63%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.01%, and the Nasdaq 100 Index ($IU ) (QQQ ) closed up +0.09%. Stock indexes Tuesday settled mixed, with the Dow Jones...

Barchart

Stocks Mixed as Debt Ceiling Talks Resume

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.16%. U.S. stocks this morning are mixed, with the Dow...

Barchart

The Vaccine Problem

To better weather future pandemics, the way countries procure vaccines needs to change radically

The Walrus

From analysis to the latest developments in health,
read the most diverse news in one place.

Obesity speeds up loss of immunity from COVID vaccines – new research

COVID vaccines are very effective, but for some groups they don’t generate as strong an immune response. These groups include older adults and people with weakened immune systems, for example due to cancer or other medical conditions. They tend to already be at heightened risk from COVID.

The Conversation

Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns

Sanofi said Friday its shot significantly reduced the risk of babies becoming hospitalized with RSV. But Sanofi stock dipped Friday.

Investors Business Daily

FDA's approval of the world's first vaccine against RSV will offer a new tool in an old fight – 4 questions answered

The U.S. Food and Drug Administration approved the world’s first vaccine to prevent the respiratory infection RSV, short for respiratory syncytial virus, on May 3, 2023. The new shot represents six decades of starts and stops in the hunt for a vaccine to curb one of the most common winter…

The Conversation

AI Drug Discovery Is a $50 Billion Opportunity for Big Pharma

Artificial intelligence can shave years off the development process, and companies like Japan’s Takeda are making large investments.

Businessweek

Read news from The Economist, FT, and more,
with one subscription

Two of the best drugs for stopping smoking aren't available in UK

'Process of making both varenicline and cytisine available feels excruciatingly slow'

Wales Online

FDA approves first vaccine for respiratory syncytial virus

The FDA has approved the first vaccine for respiratory syncytial virus (RSV).

The Hindu

The best drugs for stopping smoking that you probably can’t have – new review

When so much time and effort goes into developing the best medical treatments, we expect them to be available when we need them. The same goes for addiction treatments, so it’s worrying that two of the most effective drugs for quitting smoking aren’t available in the UK.

The Conversation

FDA approves 1st RSV vaccine for older adults

After decades of failure in the quest for an RSV vaccine, doctors are anxious to finally have something to offer — especially after a virus surge that strained hospitals last fall.

Chicago Sun-Times

FDA approves United States' first-ever RSV vaccine

GSK's RSV vaccine is approved for people aged 60 and older.

Axios

GSK Stock Jumps After Beating Pfizer, Moderna To The RSV Vaccine Finish Line

GSK stock jumped Wednesday after the drugmaker won the first-ever approval for an RSV vaccine, leading rivals Pfizer and Moderna.

Investors Business Daily

US approves first vaccine for RSV after decades of attempts

The US has approved the first vaccine for RSV, shots to protect older adults

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Pfizer Reports Dramatic Declines — But It's Not As Bad As Wall Street Expected

Pfizer reported double-digit declines across its first-quarter metrics, but beat analysts' expectations. Pfizer stock fell Tuesday.

Investors Business Daily

Dow Jones Slides On Key Economic Data. Fed Meeting Begins, While Tesla Rallies On Price Hikes.

The Dow Jones sold off 300 points Tuesday after key economic data, as the Fed's policy meeting begins. Tesla stock rallied on price hikes.

The Texas Tribune

Attorney General Ken Paxton to investigate COVID-19 vaccine makers

Long an opponent of vaccine and mask mandates, the Republican said pharmaceutical companies may have misrepresented data. Pfizer strongly disagrees.

Asharq Al-Awsat

Pfizer, BioNTech Propose EU Pays Half for Each Cancelled COVID Dose

Pfizer Inc and BioNTech's new proposal to the European Union, amid a glut of COVID-19 shots, includes a provision for member states to pay half price, or about 10 euros ($11), for each of about 70 million cancelled doses, the Financial Times reported on Sunday. The revised contract would allow…

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?

Industry analysts warn that a groundbreaking change in how Medicare buys drugs threatens industry growth, profits — and maybe patient care.

Wales Online

People urged to start wearing masks and testing thanks to new Covid strain

Experts say it is up to individuals to help stop the spread of the disease

The Guardian - UK

UK and Europe are falling behind US and China in biotech, says AstraZeneca boss

Pascal Soriot says decline in startups across Europe differs markedly from ‘explosion’ of firms and clinical trials in China

WEKU

What lessons have we learned from the COVID pandemic?

The nonpartisan Covid Crisis Group has released its investigative report, titled "Lessons from the Covid War: An Investigative Report." This is what it found.

The Guardian - UK

AstraZeneca overtakes Pfizer as crunch week for UK pharma looms

Driven by a revamped drug portfolio, AstraZeneca is expected to report revenues of $10.7bn in its latest quarterly results

The Independent UK

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

Investors Business Daily

Novavax Plummets On Downgrade: Is It The Covid Engine That Couldn't?

Novavax has a solid platform but continues to face a $700 million litigation headwind, an analyst said Thursday as he downgraded NVAX stock.

1 … 18 19 20 21

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.